Novel NIR-II fluorescent probes for biliary atresia imaging.
10.1016/j.apsb.2023.07.005
- Author:
Xiaodong ZENG
1
;
Yuqin LIAO
1
;
Xue QIAO
1
;
Ke LIANG
1
;
Qiusi LUO
1
;
Mingbo DENG
1
;
Yishen LIU
1
;
Weijing ZHANG
2
;
Xuechuan HONG
1
;
Yuling XIAO
1
Author Information
1. State Key Laboratory of Virology, Department of Cardiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
2. State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
Biliary atresia;
Early diagnosis;
Fluorescence imaging;
Hepatobiliary excretion;
Second near-infrared window
- From:
Acta Pharmaceutica Sinica B
2023;13(11):4578-4590
- CountryChina
- Language:English
-
Abstract:
Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia.
